Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today... | May 10, 2023

Related Keywords

Australia ,Sydney ,New South Wales ,Melbourne ,Victoria ,California ,United States ,San Francisco ,David Stamler ,Hannah Howlett ,Stephen Tisch ,Remy Bernarda ,European Commission ,Company Phase ,Nasdaq ,Alterity Therapeutics ,Multiple System Atrophy ,Chief Executive Officer ,Principal Investigator ,System Atrophy ,Media Contacts ,Alterity Therapeutics Limited Stock Exchange ,News ,Information ,Press Release ,End ,Han ,Bay ,023 ,Alterity ,Herapeutics ,Biotechnology ,Company ,Edicated ,O ,Developing ,Disease ,Modifying ,Treatments ,Or ,Eurodegenerative Athe Us02155x2053 ,